<原著>進行乳癌の治療におけるchemo-endocrine therapyの意義
スポンサーリンク
概要
- 論文の詳細を見る
One hundred and sixty three patients with advanced breast cancer were treated with tamoxifen (TAM), tegafur (TGF), cyclophosphamide (CPA) and adriamycin (ADR) in order to evaluate the significance of chemo-endocrine therapy in a sequential study. The dose of medication was 20 mg po daily for TAM, 600 mg po daily for TGF, and 100 mg po daily for CPA and 20 mg iv every third week for ADR. The assessment of the response was made by the criteria of the Japan Mammary Cancer Society which are similar to UICC criteria : complete response and partial response were regarded as responder and no change and progressive diseases as non-responder. Over all response rates of these regimens were 29.0% for TAM alone therary, 40.5% for TAM+TGF therary, 36.0% for TAM+TGF+CPA therapy and 40.0% for TAM+TGF+ADR therapy. No patient with visceral lesion metastasis responded to TAM alone therapy, while 25.0-55.6% of the patients responded to the chemo-endocrine therapy. There was significant difference in the effect between them. Of the patients with estrogen receptor (ER) positive, 64.3% of them responded to TAM alone therary, 50.0% to TAM+TGF therapy, 55.6% to TAM+TGF+CPA therary and 46.1% to TAM+TGF+ADR therapy. On the other hand, response rates of these therapies in patients with ER negative were 6.3%, 9.0 %, 9.0% and 12.5% respectively. Unexpectedly, the improvement of the response rate by chemo-endocrine therapy was not achieved in ER negative. The median survival period was also longer in the chemo-endocrine therapy than TAM alone therapy. As to acute and chronic toxicity, mild gastrointestinal disorders such as nausea and vomiting and slight leukopenia were observed during the treatment. New regimens for chemo-endocrine therapy with TAM, TGF, CPA and ADR to treat the advanced breast cancer were developed in this study. These regiments showed the favourable response with lower toxicities and the patients were found to be in good quality of life during the treatment.
- 近畿大学の論文
- 1987-06-25
著者
関連論文
- 三病巣の胃癌と悪性リンパ腫の同時性四重複癌の1例
- 14歳女児に認められた甲状腺乳頭癌
- ラット7,12-dimethylbenz(a)anthracene誘発乳癌におけるestramustine phosphateの抗腫瘍効果の検討
- 第53回日本肺癌学会関西支部会 : 38.当科における転移性肺癌の外科治療成績
- P-240 Collagen Gel包埋培養法による制癌剤感受性試験における接触条件の検討
- 16.乳癌骨転移の早期発見の試み
- 28.乳癌細胞に対する内分泌化学療法の影響に関する研究 : とくにDMBA乳癌における核DNA量の変化について
- 12.乳房温存手術の局所再発例の検討 : 特に温存手術適応例の検討
- 複合内分泌療法のラットDMBA誘発乳癌に対する抗腫瘍効果と内分泌動態
- 進行乳癌の治療におけるchemo-endocrine therapyの意義